ADC Therapeutics Showcases Promising Zynlonta Data in Marginal Zone Lymphoma and Secures $105M in Funding

1. ADC Therapeutics, a clinical-stage biotechnology company, has announced positive early results for its drug Zynlonta (loncastuximab tesirine) in treating marginal zone lymphoma (MZL).
2. Zynlonta is an antibody-drug conjugate (ADC) designed to target CD19, a protein expressed on the surface of various B-cell malignancies, including MZL.
3. The company has raised $105 million through a share sale, which will help fund further development of Zynlonta and other pipeline products.
4. ADC Therapeutics is currently conducting a Phase II clinical trial to evaluate the safety and efficacy of Zynlonta in patients with relapsed or refractory MZL.
5. Marginal zone lymphoma is a slow-growing type of non-Hodgkin lymphoma that originates in the lymphatic system's marginal zones.
6. The positive early results from the Zynlonta trial suggest that the drug could potentially offer a new treatment option for patients with MZL, who currently have limited therapies available.
7. ADC Therapeutics specializes in the development of ADCs, which combine the targeting ability of monoclonal antibodies with the cancer-killing power of cytotoxic drugs, to create targeted and potentially more effective cancer therapies.
8. The company's successful share sale and the promising Zynlonta data demonstrate the potential of ADC Therapeutics' ADC platform and its commitment to advancing innovative cancer treatments.